{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:28:11Z","timestamp":1736832491759,"version":"3.33.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cbi.2024.111342","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T02:16:39Z","timestamp":1733364999000},"page":"111342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Critical considerations for co-administering rivaroxaban and vonoprazan: Unveiling potential pharmacokinetic interactions"],"prefix":"10.1016","volume":"406","author":[{"given":"Xiao-yu","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-chao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-hao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-peng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5169-4696","authenticated-orcid":false,"given":"Jian-chang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2024.111342_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/09537104.2018.1557618","article-title":"The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis","volume":"31","author":"Schultz","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.cbi.2024.111342_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-015-0317-5","article-title":"Hepatotoxicity of new oral anticoagulants (NOACs)","volume":"38","author":"Liakoni","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.cbi.2024.111342_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8886210","article-title":"Rivaroxaban: expanded role in cardiovascular disease management-A literature review","volume":"2021","author":"Ajmal","year":"2021","journal-title":"Cardiovascular Therapeut."},{"key":"10.1016\/j.cbi.2024.111342_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1472-8206.2011.00981.x","article-title":"Pharmacodynamic and pharmacokinetic basics of rivaroxaban","volume":"26","author":"Kreutz","year":"2012","journal-title":"Fund. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2024.111342_bib5","first-page":"1056","volume":"vol. 35","author":"Yeh","year":"2015"},{"key":"10.1016\/j.cbi.2024.111342_bib6","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.cbi.2024.111342_bib7","article-title":"Plasma rivaroxaban level in patients with early stages of chronic kidney disease-relationships with renal function and clinical events","volume":"13","author":"Sin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2024.111342_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cbi.2024.111342_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2021.11.008","article-title":"Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban, or dabigatran","volume":"135","author":"Holt","year":"2022","journal-title":"Am. J. Med."},{"key":"10.1016\/j.cbi.2024.111342_bib10","article-title":"Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: case series","volume":"11","author":"\u0160imi\u010devi\u0107","year":"2023","journal-title":"Pharmacy (Basel, Switzerland)"},{"key":"10.1016\/j.cbi.2024.111342_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620925923","article-title":"Analysis of effectiveness, safety, and bleeding related to rivaroxaban in elderly patients","volume":"26","author":"Hou","year":"2020","journal-title":"Clinical and applied thrombosis\/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1016\/j.cbi.2024.111342_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008064","article-title":"Renal function assessment and direct-acting oral anticoagulants dosing: are we entering a new age?","volume":"14","author":"Smith","year":"2021","journal-title":"Circulation. Cardiovasc. Quality Outcomes"},{"key":"10.1016\/j.cbi.2024.111342_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jama.2018.9257","article-title":"Andexxa-an antidote for apixaban and rivaroxaban","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2024.111342_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5482\/ha-2012030001","article-title":"[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]","volume":"32","author":"Koscielny","year":"2012","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.cbi.2024.111342_bib15","article-title":"The influence of CYP3A4 genetic polymorphism and proton pump inhibitors on osimertinib metabolism","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2024.111342_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/09674845.2016.1195151","article-title":"Laboratory monitoring of rivaroxaban and assessment of its bleeding risk","volume":"73","author":"Zhang","year":"2016","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.cbi.2024.111342_bib17","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.cbi.2024.111342_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2015.06.081","article-title":"Fatal intracerebral bleeding under rivaroxaban","volume":"201","author":"St\u00f6llberger","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cbi.2024.111342_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/dmd.116.073890","article-title":"Application of static modeling --in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies","volume":"45","author":"Cheong","year":"2017","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2024.111342_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2024.111342_bib21","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-019-01183-0","article-title":"Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs)","volume":"79","author":"Herink","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cbi.2024.111342_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2024.111342_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/dmd.122.000928","article-title":"Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib","volume":"50","author":"Wang","year":"2022","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2024.111342_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0026-895X(24)12335-8","article-title":"Cloning of CYP2J2 gene and identification of functional polymorphisms","volume":"61","author":"King","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2024.111342_bib25","article-title":"Evaluation of herb-drug interaction between danshen and rivaroxaban in rat and human liver microsomes","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2024.111342_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10557-020-07129-z","article-title":"Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant","volume":"36","author":"Zhao","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.cbi.2024.111342_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/13880209.2020.1785510","article-title":"Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats","volume":"58","author":"Chong","year":"2020","journal-title":"Pharmaceut. Biol."},{"key":"10.1016\/j.cbi.2024.111342_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.123.001767","article-title":"Gene polymorphisms and drug-drug interactions determine the metabolic profile of blonanserin","volume":"388","author":"Ye","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2024.111342_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119975","article-title":"Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis","volume":"291","author":"Zechner","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.cbi.2024.111342_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","article-title":"Cardiovascular drug therapy in the elderly: benefits and challenges","volume":"8","author":"Fleg","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"volume":"vol. 153","year":"2020","author":"Koutsilieri","key":"10.1016\/j.cbi.2024.111342_bib31"},{"key":"10.1016\/j.cbi.2024.111342_bib32","first-page":"Cd002783","article-title":"Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb","volume":"1","author":"Broderick","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cbi.2024.111342_bib33","first-page":"11","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","author":"Heestermans","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cbi.2024.111342_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11040250","article-title":"Drug-drug interactions leading to adverse drug reactions with rivaroxaban: a systematic review of the literature and analysis of VigiBase","volume":"11","author":"Fernandez","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.cbi.2024.111342_bib35","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2024.111342_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10120-020-01105-0","article-title":"Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study","volume":"24","author":"Tomida","year":"2021","journal-title":"Gastric Cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"key":"10.1016\/j.cbi.2024.111342_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/a-2031-0874","article-title":"Endoscopic submucosal dissection techniques and technology: European society of gastrointestinal endoscopy (ESGE) technical review","volume":"55","author":"Lib\u00e2nio","year":"2023","journal-title":"Endoscopy"},{"issue":"Suppl 4","key":"10.1016\/j.cbi.2024.111342_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1289\/ehp.97105s4759","article-title":"Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity","volume":"105","author":"Hong","year":"1997","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.cbi.2024.111342_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dmpk.2017.10.004","article-title":"Terfenadine metabolism of human cytochrome P450 2J2 containing genetic variations (G312R, P351L and P115L)","volume":"33","author":"Jeong","year":"2018","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.cbi.2024.111342_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/03602532.2016.1188938","article-title":"CYP2J2 - regulation, function and polymorphism","volume":"48","author":"Murray","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2024.111342_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1186824","article-title":"Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724004885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724004885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:47:53Z","timestamp":1736804873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279724004885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":41,"alternative-id":["S0009279724004885"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2024.111342","relation":{},"ISSN":["0009-2797"],"issn-type":[{"type":"print","value":"0009-2797"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical considerations for co-administering rivaroxaban and vonoprazan: Unveiling potential pharmacokinetic interactions","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2024.111342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111342"}}